News Author: Jennifer Smith Publish date: February 20, 2019
The product won’t be available before 2020.
News Author: Jennifer Smith Publish date: February 17, 2019
Patients with this subtype had distinct molecular features and poor prognosis.
News Author: Jennifer Smith Publish date: February 16, 2019
Dr. Caron A. Jacobson outlines factors hindering cross-trial comparisons of CAR T-cell therapies.
News Author: Jennifer Smith Publish date: February 15, 2019
The approval for this indication is supported by the phase 3 ECHELON-1 trial.
News Author: Jennifer Smith Publish date: February 14, 2019
Just 10 of 121 patients responded to nivolumab in a phase 2 trial and researchers aren’t sure why this particular group of patients responded.
News Author: Jennifer Smith Publish date: February 11, 2019
Dasatinib will be available in tablet form and as a powder for oral suspension.
News Author: Jennifer Smith Publish date: February 9, 2019
Dr. Navneet Majhail will assume the office of ASBMT president at the end of February.
Video Author: Jennifer Smith Publish date: February 8, 2019
LA JOLLA, CALIF. – Researchers found the risk of second malignancy was highest among MF patients aged 30 to 50 years and patients who had tumor sta...
Video Author: Jennifer Smith Publish date: February 7, 2019
LA JOLLA, CALIF. – A small number of patients experienced disease stabilization or regression on cobomarsen.
News Author: Jennifer Smith Publish date: February 6, 2019
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia pu...
Video Author: Jennifer Smith Publish date: February 6, 2019
LA JOLLA, CALIF. – Some CTCL patients experienced relief from itching after just one pill.
Video Author: Jennifer Smith Publish date: February 5, 2019
LA JOLLA, CALIF. – Researchers plan to expand the duvelisib plus romidepsin arm to better understand the occurrence of transaminitis and assess the...
News Author: Jennifer Smith Publish date: February 1, 2019
BI-1206 is under investigation in a phase 1/2a study.
Video Author: Jennifer Smith Publish date: January 31, 2019
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
News Author: Jennifer Smith Publish date: January 30, 2019
The designation is based on results from a phase 1 trial of 35 patients.
